Sex Differences in Baseline Cardiometabolic Phenotype and HbA1c Treatment Response to Dapagliflozin With or Without Semaglutide: Real-World Evidence From Saudi Arabia

Coverage, in order

1. 2d ago
   Research Square obscure study observational

   Sex Differences in Baseline Cardiometabolic Phenotype and HbA1c Treatment Response to Dapagliflozin With or Without Semaglutide: Real-World Evidence From Saudi Arabia

   Sex differences in cardiometabolic risk profiles are well recognized, yet treatment response data for dapagliflozin with or without semaglutide remain limited in real-world settings, particularly in Middle Eastern populations. Using a descriptive, sex-disaggregated analysis of a real-world cohort…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.